Clinical Trial: A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07358546) titled 'A Study of Efimosfermin Alfa in Adults With Hepatic Impairment' on Jan. 14.

Brief Summary: This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic liver disease, with and without significant alcohol consumption.

Study Start Date: Jan. 30

Study Type: INTERVENTIONAL

Condition: Non-alcoholic Fatty Liver Disease

Intervention: DRUG: Efimosfermin alfa

Efimosfermin alfa to be administrated subcutaneously

Recruitment Status: NOT_YET_RECRUITING

Sponsor: GlaxoSmithK...